Johnson & Johnson (JNJ) Stock Price, Fundamentals & Analysis

What JNJ does

Johnson & Johnson (JNJ) is a US-based healthcare company that researches, manufactures, and sells products across two main segments: Innovative Medicine and MedTech. The Innovative Medicine segment covers therapeutic areas such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism, while the MedTech segment focuses on surgery, orthopedics, cardiovascular devices, and vision products. It is part of the S&P 500 and operates alongside peers such as Merck & Co. (MRK) and Viatris (VTRS).

Key numbers explained

• 269.17 USD — the current share price, which is the latest trading price of one JNJ share.
• 31.3 trailing P/E ratio — the price investors pay per dollar of the last 12 months’ earnings; a higher number can reflect higher expectations or a richer valuation.
• 22.2 forward P/E ratio — similar to the trailing P/E but based on expected future earnings, which can change as analyst estimates update.
• 8.61 USD earnings per share (trailing 12 months) — the portion of net income attributable to each share over the last year.
• 1.99% dividend yield — the annual dividend payment expressed as a percentage of the current share price, showing the cash return from dividends alone.
• 1.99% dividend yield with an exDividendDate of 25 aug. 2026 — the date after which a buyer is no longer entitled to the next dividend payment.
• 61% share of earnings paid out as dividends — the proportion of net income returned to shareholders as dividends, indicating a relatively generous payout policy.
• 0.24 beta — a measure of price volatility relative to the market; a beta below 1 suggests JNJ has historically moved less than the broader market.
• 52.4% price change over the last 52 weeks — the total return from the price one year ago to today, ignoring dividends.
• 21.5% profitMargin — the percentage of revenue that remains as net income after all expenses.
• 29.2% operatingMargin — the percentage of revenue left after covering operating costs, before interest and taxes.
• 25.7% returnOnEquity — how effectively the company generates profit from shareholders’ equity.
• 57.7% debt-to-equity ratio — the proportion of debt compared to equity, indicating the company’s financial leverage.
• 7.63 priceToBook — the ratio of market price to book value per share, often used to assess whether a stock trades at a premium to its accounting value.

Recent news

Recent headlines reference questions about AbbVie’s disclosures, a bullish case for Pfizer, and the growing surgical devices market. Other stories highlight new clinical data for TECVAYLI and DARZALEX FASPRO in multiple myeloma, a list of elite dividend stocks with diversified pipelines, and an analysis of the market’s reaction to JNJ’s OTTAVA results.

What to watch

Investors typically monitor JNJ alongside peers such as Cardinal Health (CAH), Illumina, Inc. (ILMN), Bio-Techne (TECH), Incyte (INCY), and Steris (STE) for sector trends. Key factors include pipeline developments and regulatory decisions in its Innovative Medicine and MedTech segments, macroeconomic conditions that affect healthcare spending, currency movements for its global operations, and the company’s ability to sustain its dividend and manage leverage. The next earnings release is scheduled for 13 oct. 2026.